Intercept Pharmaceuticals is a biopharmaceutical company focused on developing and delivering novel medicines for people living with rare and serious liver diseases. The company has pioneered a scientific platform centered around Farnesoid X Receptor (FXR) biology, which has applications for conditions like primary biliary cholangitis (PBC) and severe alcohol-associated hepatitis. Intercept is committed to progressing its research portfolio and advancing treatments for liver diseases by addressing high unmet medical needs. With a team dedicated to innovation and collaboration, the company aims to have a significant impact on therapeutic development and patient care. Headquartered in Morristown, NJ, Intercept is known for its FDA-approved FXR agonist used in second-line treatment of PBC.